Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Telemedicine Outreach for Post Traumatic Stress in CBOCs
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Status: Enrolling
Updated:  12/31/1969
Central Arkansas Veterans Healthcare System (North Little Rock)
mi
from 43215
North Little Rock, AR
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Status: Enrolling
Updated: 12/31/1969
Central Arkansas Veterans Healthcare System (North Little Rock)
mi
from 43215
North Little Rock, AR
Click here to add this to my saved trials
Cognitive Training to Enhance VA Work Program Outcomes
Cognitive Training to Enhance VA Work Program Outcomes
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Healthcare System
535
mi
from 43215
West Haven, CT
Cognitive Training to Enhance VA Work Program Outcomes
Cognitive Training to Enhance VA Work Program Outcomes
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Healthcare System
535
mi
from 43215
West Haven, CT
Click here to add this to my saved trials
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Eskenazi Hospital
167
mi
from 43215
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Eskenazi Hospital
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
166
mi
from 43215
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
University Hospital
186
mi
from 43215
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
University Hospital
186
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Measures to Lower the Stress Response in Pediatric Cardiac Surgery
Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF).
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Measures to Lower the Stress Response in Pediatric Cardiac Surgery
Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF).
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
National Children s Health Study
Vanguard Phase of the National Children s Study
Status: Enrolling
Updated:  12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
322
mi
from 43215
Bethesda, MD
National Children s Health Study
Vanguard Phase of the National Children s Study
Status: Enrolling
Updated: 12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures
Status: Enrolling
Updated:  12/31/1969
St Luke's - Roosevelt Hospital Center
479
mi
from 43215
New York, NY
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures
Status: Enrolling
Updated: 12/31/1969
St Luke's - Roosevelt Hospital Center
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Shanti Clinical Trials
1923
mi
from 43215
Colton, CA
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Shanti Clinical Trials
1923
mi
from 43215
Colton, CA
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Center for Healing the Human Spirit
1985
mi
from 43215
Tarzana, CA
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Center for Healing the Human Spirit
1985
mi
from 43215
Tarzana, CA
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Resource Center
481
mi
from 43215
Englewood Cliffs, NJ
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Resource Center
481
mi
from 43215
Englewood Cliffs, NJ
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Resource Center
478
mi
from 43215
New York, NY
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Resource Center
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Dynamics Centre
9466
mi
from 43215
Westmead,
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Dynamics Centre
9466
mi
from 43215
Westmead,
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Skyland Behavioral Health Associates , P.A.
302
mi
from 43215
Asheville, NC
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Skyland Behavioral Health Associates , P.A.
302
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center
306
mi
from 43215
Winston-Salem, NC
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
A Comprehensive Disease Management Program for Medically-Complex Substance Users
A Comprehensive Disease Management Program for Medically-Complex Substance Users
Status: Enrolling
Updated:  12/31/1969
East Baltimore Medical Center
344
mi
from 43215
Baltimore, MD
A Comprehensive Disease Management Program for Medically-Complex Substance Users
A Comprehensive Disease Management Program for Medically-Complex Substance Users
Status: Enrolling
Updated: 12/31/1969
East Baltimore Medical Center
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
166
mi
from 43215
Indianapolis, IN
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Columbia University, 622 W. 168th St.
477
mi
from 43215
New York, NY
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Columbia University, 622 W. 168th St.
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
641
mi
from 43215
Boston, MA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Neurobehavioral Center
332
mi
from 43215
Columbia, MD
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Neurobehavioral Center
332
mi
from 43215
Columbia, MD
Click here to add this to my saved trials
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
1636
mi
from 43215
Tucson, AZ
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
1636
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates
1643
mi
from 43215
Tucson, AZ
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates
1643
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group
655
mi
from 43215
Bentonville, AR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group
655
mi
from 43215
Bentonville, AR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
659
mi
from 43215
Fayetteville, AR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
659
mi
from 43215
Fayetteville, AR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
1154
mi
from 43215
Aurora, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers, Site #191
1171
mi
from 43215
Boulder, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers, Site #191
1171
mi
from 43215
Boulder, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
1161
mi
from 43215
Denver, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network-St. Vincent's
670
mi
from 43215
Jacksonville, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network-St. Vincent's
670
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network-Southside
670
mi
from 43215
Jacksonville, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network-Southside
670
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network
681
mi
from 43215
Orange Park, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network
681
mi
from 43215
Orange Park, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Physician Group
243
mi
from 43215
Danville, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Physician Group
243
mi
from 43215
Danville, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Central Illinois
314
mi
from 43215
Decatur, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Central Illinois
314
mi
from 43215
Decatur, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Crossroads Cancer Center
300
mi
from 43215
Effingham, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Crossroads Cancer Center
300
mi
from 43215
Effingham, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Foundation Physician Services
286
mi
from 43215
Mattoon, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Foundation Physician Services
286
mi
from 43215
Mattoon, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Cancer Center
274
mi
from 43215
Urbana, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Cancer Center
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Baptist Hospital East
183
mi
from 43215
Louisville, KY
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Baptist Hospital East
183
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
349
mi
from 43215
Baltimore, MD
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
349
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Center for Cancer & Blood Disorders
320
mi
from 43215
Bethesda, MD
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Center for Cancer & Blood Disorders
320
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer & Hematology Center of Western Michigan
247
mi
from 43215
Grand Rapids, MI
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer & Hematology Center of Western Michigan
247
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota CCOP-Unity Hospital
629
mi
from 43215
Fridley, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota CCOP-Unity Hospital
629
mi
from 43215
Fridley, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota CCOP-St. Johns
616
mi
from 43215
Maplewood, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota CCOP-St. Johns
616
mi
from 43215
Maplewood, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
499
mi
from 43215
Columbia, MO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
499
mi
from 43215
Columbia, MO
Click here to add this to my saved trials